tbuckley/cabot-search huggingface dataset:
Late-breaking abstract: Temporary improvement of serum albumin in PIZ mice after transplantation of stem cell-derived hepatocyte-like cells
Authors: Sandra Winkler, Madlen Hempel, Sandra Brückner, Bruno Christ
Journal: European Respiratory Journal (2014)

Background: Hepatocyte-like cells can be generated from adipose tissue derived stem cells and display a promising resource as alternative to whole organ or hepatocyte transplantation, especially in chronic/metabolic liver diseases such as α-1-antitrypsin deficiency (AATD).  Aims: The aim of this work was to analyze the therapeutic potential of autologous hepatocyte-like cells generated from adipose tissue-derived mesenchymal stem cells to improve liver function in the PIZ mouse model of AATD.  Methods: MSCs were isolated from Pfp/Rag2-/- mice. Cells were cultured and differentiated for 14 days into hepatocyte-like cells. Albumin expression was measured on the mRNA level as a major liver functional parameter. 0.8x10^6 cells were transplanted into male and female PIZ mice. PBS injection served as a control. 1 and 3 weeks after transplantation, mice were sacrificed and samples were taken.  Results: After 14 days of differentiation, hepatocyte-like cells adopted hepatocyte-specific functions in vitro and expressed albumin. 1 week post-transplantation into livers of PIZ mice, serum albumin levels increased significantly compared to controls (PBS). Furthermore, the liver/bodyweight ratio of animals receiving stem cell transplants increased indicating overall improvement of body homeostasis. 3 weeks post-transplantation, serum albumin levels decreased again indicating loss of the cell transplants.  Conclusion: The transplantation of hepatocyte-like cells temporary incresed serum albumin levels in PIZ mice indicating a functional improvement by the differentiated MSC. Yet, a repeated administration of hepatocyte-like cells seems to be required to maintain permanent support.
Identification of la Antigens on the Murine Adenocarcinoma L T-85&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN4"&gt;4&lt;/xref&gt;
Authors: M A Giedlin, W J Martin, G N Callahan
Journal: JNCI Journal of the National Cancer Institute (1983)

Antigens associated with the H-2Kk and I-Ak regions of the major histocompatibility complex have been identified with monoclonal antibodies on an in vivo grown murine alveologenic adenocarcinoma, LT-85. Immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis demonstrated differences in the molecular structure of I-Ak region-coded antigens between LT-85 and host C3H/HeN mammary tumor virus-negative (MTV-) or autologous C3HfB/HeN splenocytes. Ia antigens derived from LT-85 tumor cells exhibited both an increased heterogeneity in the alpha-chain and a lower apparent molecular weight in the beta-chain. Tryptic peptide mapping of the I-Ak antigen alpha- and beta-chains derived from C3H/HeN MTV- mice and LT-85 tumor cells revealed a single peptide difference in the beta-chains of these antigens. Results obtained with neuraminidase-treated I-Ak beta-chains indicated that this difference was not due to sialic and content. Maintenance of LT-85 in vitro, even for short periods, resulted in the loss of these I-Ak antigens. However, this loss of I-Ak antigen expression was fully reversible with in vivo growth.
Development of a Hematology/Oncology ICD-10 Documentation Job Aid
Authors: Daniel B. Martin, Sean Silas, Audrey Covner, Paul C. Hendrie, F. Marc Stewart
Journal: Journal of the National Comprehensive Cancer Network (2015)

Conversion to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) was mandated for October 1, 2014, but was delayed by one year. ICD-10 accommodates newly developed diagnoses and procedures and is expected to help measure quality of care. When implemented, it will impact oncology practices because of conversion costs, loss of productivity, and billing problems. Clinical documentation must meet the specificity required by ICD-10 codes or risk denial of payments, which are projected to dramatically increase. In preparation for the now delayed conversion, the ICD-10 transition team at the Seattle Cancer Care Alliance (SCCA) examined the ICD-10 codes for primary hematology/oncology diagnoses and comorbidities of cancer and therapy seen at our institution to identify the need for and feasibility of developing a printable job aid to guide clinical documentation. We found that the variable complexity of ICD-10 codes in hematology/oncology frequently requires nonintuitive specificity likely to be overlooked without prompting. We were able to develop a succinct and facile documentation aid usable in both electronic and printed forms that includes all hematology/oncology diagnoses and the comorbidities most frequently seen in our multidisciplinary institution. This document is organized in a notebook format for easy review and will be continuously improved with feedback from practitioners. It is available for free download from the SCCA Web site.
Electron Microscopic Study on Acute Thymic Involution Induced by Polyoma Virus Infection
Authors: Masakatsu Imamura, Tsutomu Matsuyama, Kentaro Toh, Tomizo Okuyama
Journal: JNCI Journal of the National Cancer Institute (1971)

Acute thymic involution induced by polyoma virus (PV) in AKR mice was studied ultrastructurally. The involuted thymuses were characterized by the presence of abundant nuclear debris derived from thymic lymphocytes (TL). Besides intercellular spaces, TL were included within the cytoplasm of epithelial reticular cells and macrophages. In epithelial cell cytoplasm, TL often contacted the nuclear membrane, and occasionally the limiting membrane, which surrounded these TL, was obscured. PV particles were often detected in epithelial cell nuclei and in phagosomes of macrophages. Their presence in epithelial cell nuclei and the consequent development of epithelial thymoma in adults strongly suggest that epithelial cells in the thymus are susceptible to PV and are transformed just after PV infection at the neonatal period. Their roles in lymphogenesis in earlier life and in regulation of peripheral lymphocytes suggest that TL destruction is caused by the functional alteration of the epithelial reticular cells. PV particles were not around most of the destroyed TL, and direct viral participation in TL destruction was not evident. Peculiar osmiophilic dense structures occasionally observed near the altered TL nuclei were studied morphologically and compared with structures detected in thymuses involuted by cortisone or X irradiation.
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
Authors: R. Dorr, C. Karanes, C. Spier, T. Grogan, J. Greer, J. Moore, B. Weinberger, G. Schiller, T. Pearce, M. Litchman, W. Dalton, D. Roe, A. F. List
Journal: Journal of Clinical Oncology (2001)

To determine the maximum-tolerated dose, pharmacokinetic interaction, and activity of PSC 833 compared with daunorubicin (DNR) and cytarabine in patients with poor-risk acute myeloid leukemia.Patients received ara-C 3 g/m(2)/d on 5 consecutive days, followed by an IV loading dose of PSC 833 (1.5 mg/kg) and an 84-hour continuous infusion escalating from 6, 9, or 10 mg/kg/d. Daunorubicin was administered as a 72-hour continuous infusion at 34 or 45 mg/m2/d [corrected]. Responding patients received consolidation chemotherapy with DNR pharmacokinetics performed without PSC-833 on day 1, and with PSC-833 on day 4. Response was correlated with expression of P-glycoprotein and lung resistance protein (LRP), and in vitro sensitization of leukemia progenitors to DNR cytotoxicity by PSC 833.All 43 patients are assessable for toxicity and response. Grade 3 or greater hyperbilirubinemia (70%) was the only dose-dependent toxicity. Four patients (9%) succumbed to treatment-related complications. Twenty-one patients (49%) achieved a complete remission or restored chronic phase, including 10 of 20 patients treated at the maximum-tolerated dose of 10 mg/kg/d of PSC-833 and 45 mg/m(2) of DNR. The 95% confidence interval for complete response was 33.9% to 63.7%. Administration of PSC 833 did not alter the mean area under the curve for DNR, although clearance decreased approximately two-fold (P =.04). Daunorubicinol clearance decreased 3.3-fold (P =.016). Remission rates were not effected by mdr-1 expression, but LRP overexpression was associated with chemotherapy resistance.Combined treatment with infused PSC 833 and DNR is well tolerated and has activity in patients with poor risk acute myeloid leukemia. Administration of PSC 833 delays elimination of daunorubicinol, but yields variable changes in DNR systemic exposure.
ON THE PATHOGENESIS OF INCONTINENTIA PIGMENTI.
Authors: G. H. FINDLAY
Journal: British Journal of Dermatology (1952)

Journal Article ON THE PATHOGENESIS OF INCONTINENTIA PIGMENTI: With Observations on an Associated Eye Disturbance Resembling Retrolental Fibroplasia Get access G. H. FINDLAY G. H. FINDLAY Department of Internal Medicine, University of Pretoria Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 64, Issue 4, 1 April 1952, Pages 141–146, https://doi.org/10.1111/j.1365-2133.1952.tb16177.x Published: 01 April 1952
A follow-up of patients with a new diagnosis of asthma - characteristics, prognosis and risk factors
Authors: Karin Lisspers, Christer Janson, Josefin Sundh, Scott Montgomery, Mary Kämpe, Eva Österlund Efraimsson, Anna Ericson, Bjorn Stallberg
Journal: European Respiratory Journal (2013)

Objective:  To study patients with a new diagnosis of asthma in a seven year follow-up.   Method:  A survey in 2005 to 1725 randomly selected patients, 18-75 years, with a diagnosis of asthma. Response rate 71%. Medical records data 2000-2003 were reviewed and a follow-up was performed in 2012. This study analyses data from the 2005 and 2012 surveys regarding patients that received their asthma diagnosis 2000-2003. Asthma control according to GINA, quality of life (MiniAQLQ) and BMI from questionnaire.   Results:  Of 1211 patients in the 2005 survey 339, 79% in primary care and 58% women, were diagnosed 2000-2003. A total of 194 patients, women 58%, participated in the follow-up 2012. Mean age of women 2012 was 57.3 years (SD14.5), men 57.5 years (SD13.5); daily smoking 6% and 6%; allergic rhinitis 50% and 52%; BMI >30 25% and 23% respectively. No current asthma stated by 27% of the women and 21% of the men.  Treatment 2005: ICS women 46%, men 47%; fixed combination 23%, 21% respectively. In 2012: ICS women 23%, men 25%; fixed combination 31%, 29% respectively.  Asthma control 2005: women 47%, men 56% and 2012: 55% and 58% respectively. MiniAQLQ 2005: women 5.61 (95%CI 5.41-5.80), men 5.82 (95%CI 5.58-6.05) and 2012: women 5.87 (95%CI 5.66-6.08), men 5.89 (95%CI 5.64-6.13).  Patients with BMI >30 in 2005 had OR 2.1 (95%CI 1.00-4.45), and patients with allergic rhinitis in 2012 had OR 2.56 (95%CI 1.39-4.73) for not achieving asthma control in 2012, adjusted for age and sex.   Conclusion:  Uncontrolled asthma and impaired quality of life were common in this follow-up of patients diagnosed about ten years earlier. High BMI and allergic rhinitis were associated with uncontrolled asthma.
Inspiratory Maneuver Effects on Peak Expiratory Flow
Authors: GEORGE E. TZELEPIS, SPYROS ZAKYNTHINOS, THEODORE VASSILAKOPOULOS, STEPHANOS GEROULANOS, CHARIS ROUSSOS
Journal: American Journal of Respiratory and Critical Care Medicine (1997)

We investigated the effects of two different inspiratory maneuvers (fast or slow) on the ability of normal subjects to generate peak expiratory flows (PEF) and maximal dynamic expiratory pressures (Pexp) during the performance of a forced vital capacity maneuver. During the fast maneuver (F), the subject inspired rapidly to total lung capacity (TLC) and immediately performed a maximal expiration, whereas in the slow maneuver (S) the subject inspired slowly to TLC, paused for 4 –5 s at TLC and then performed a maximal expiration. Ten normal subjects performed a series of such maneuvers. In addition to PEF and Pexp, we measured EMG activity of abdominal (EMGabd) and rib cage muscles, and lung elastic recoil pressure (PesL). Overall, F yielded higher PEF values than S (by approximately 7%); in addition, PesL, Pexp, rate of rise of Pexp (dPexp / dt), and EMGabd were similarly higher with F than with S (p < 0.05 for all). Analysis of individual data showed that the intermaneuver differences in PEF were largely explained by differences in PesL, Pexp or dPexp/dt. Our data suggest that, in comparison with the slow maneuver, the fast maneuver induces a greater change in both the lung elastic recoil and expiratory muscle activation which account for differences in PEF between the two maneuvers. The enhanced expiratory muscle activation with the fast maneuver suggests a specific inspiratory-expiratory muscle interaction analogous to agonist-antagonist interactions described for skeletal muscles.
Methotrexate Inhibits NF‐κB Activity Via Long Intergenic (Noncoding) RNA–p21 Induction
Authors: Charles F. Spurlock, John T. Tossberg, Brittany K. Matlock, Nancy J. Olsen, Thomas M. Aune
Journal: Arthritis & Rheumatology (2014)

To determine interrelationships between the expression of long intergenic (noncoding) RNA-p21 (lincRNA-p21), NF-κB activity, and responses to methotrexate (MTX) in rheumatoid arthritis (RA) by analyzing patient blood samples and cell culture models.Expression levels of long noncoding RNA and messenger RNA (mRNA) were determined by quantitative reverse transcription-polymerase chain reaction. Western blotting and flow cytometry were used to quantify levels of intracellular proteins. Intracellular NF-κB activity was determined using an NF-κB luciferase reporter plasmid.Patients with RA expressed reduced basal levels of lincRNA-p21 and increased basal levels of phosphorylated p65 (RelA), a marker of NF-κB activation. Patients with RA who were not treated with MTX expressed lower levels of lincRNA-p21 and higher levels of phosphorylated p65 compared with RA patients treated with low-dose MTX. In cell culture using primary cells and transformed cell lines, MTX induced lincRNA-p21 through a DNA-dependent protein kinase catalytic subunit (DNA PKcs)-dependent mechanism. Deficiencies in the levels of PRKDC mRNA in patients with RA were also corrected by MTX in vivo. Furthermore, MTX reduced NF-κB activity in tumor necrosis factor α-treated cells through a DNA PKcs-dependent mechanism via induction of lincRNA-p21. Finally, we observed that depressed levels of TP53 and lincRNA-p21 increased NF-κB activity in cell lines. Decreased levels of lincRNA-p21 did not alter NFKB1 or RELA transcripts; rather, lincRNA-p21 physically bound to RELA mRNA.Our findings support a model whereby depressed levels of lincRNA-p21 in RA contribute to increased NF-κB activity. MTX decreases basal levels of NF-κB activity by increasing lincRNA-p21 levels through a DNA PKcs-dependent mechanism.
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities
Authors: Haruka Itakura, Achal S. Achrol, Lex A. Mitchell, Joshua J. Loya, Tiffany Liu, Erick M. Westbroek, Abdullah H. Feroze, Scott Rodriguez, Sebastian Echegaray, Tej D. Azad, Kristen W. Yeom, Sandy Napel, Daniel L. Rubin, Steven D. Chang, Griffith R. Harsh, Olivier Gevaert
Journal: Science Translational Medicine (2015)

Quantitative imaging stratifies glioblastoma into three different phenotypes with distinct molecular activities independent of established molecular markers and clinical status.
Open access to tree genomes: the path to a better forest
Authors: David B Neale, Charles H Langley, Steven L Salzberg, Jill L Wegrzyn
Journal: Genome biology (2013)

An open-access culture and a well-developed comparative-genomics infrastructure must be developed in forest trees to derive the full potential of genome sequencing in this diverse group of plants that are the dominant species in much of the earth's terrestrial ecosystems.
Abstract 2812: Accuracy of Delayed Hyper-Enhancement Cardiac Magnetic Resonance Imaging in Patients with Endomyocardial Biopsy Positive Amyloidosis: A Multimodality Imaging Study
Authors: Bethany A Austin, Scott Flamm, Rene Rodriguez, Carmela Tan, W.H. Wilson Tang, David O Taylor, Randall C Starling, Milind Y Desai
Journal: Circulation (2008)

In patients with suspected cardiac amyloidosis (CA), endomyocardial biopsy (EMB) provides definitive diagnosis. On delayed hyper-enhancement cardiac magnetic resonance (DHE-CMR), CA has a characteristic diffuse enhancement of the subendocardium extending to adjacent myocardium. We sought to determine the accuracy of DHE-CMR, as compared to standard noninvasive parameters, in the diagnosis of patients with suspected CA who underwent EMB. A total of 37 consecutive patients (mean age 60 years, 70 % men, 57 % with NYHA class &gt; 2) with suspected CA underwent electrocardiography (ECG), transthoracic echocardiography (TTE), DHE-CMR (Siemens 1.5 T scanner, Erlangen, Germany) and EMB between 1/05 and 4/08. Low voltage on ECG was defined as the sum of S wave in lead V1 + R wave in lead V5 or V6 &lt; 15mm. Standard TTE (including tissue Doppler) parameters and myocardial performance index (MPI) [(isovolumic contraction time + isovolumic relaxation time)/ejection time] were recorded. CMR was considered positive in the presence of DHE of the subendocardium extending to the adjacent myocardium. Fifteen patients had EMB-positive CA, while 22 had negative EMB. Using EMB as the gold standard, there was 1 false-positive and 1 false-negative CMR. Sensitivity and specificity of DHE-CMR for CA was 93% and 95%, and, positive predictive value (PV) and negative PV of DHE-CMR in the diagnosis of CA were 93 % and 95 % respectively. Logistic regression analysis demonstrating the association between EMB-positive CA and various noninvasive parameters is shown in the Table . DHE-CMR is highly accurate in noninvasive diagnosis of EMB-positive CA as compared to standard ECG and TTE criteria. Incremental prognostic value of DHE-CMR in CA for clinical outcomes needs to be determined. Table: Logistic univariate regression analysis testing the association between endomyocardial biopsy proven cardiac amyloidosis and various noninvasive imaging parameters.
Rethinking mental health: a European WHO perspective.
Authors: Wolfgang Rutz
Journal: World Psychiatry (2003)

In spite of recent clinical and research advances, an increased burden of mortality and morbidity related to stress and mental ill health can be noted, especially in European societies and populations undergoing stressful transitions and dramatic changes. A societal syndrome, consisting of depression, suicide, abuse, risk-taking and violent behaviour as well as vascular morbidity and mortality, can be observed, reflecting individual psychopathology related to disturbances of the serotonin metabolism as one of the oldest, most basic cerebral instruments of mankind to survive, to socialize, to cope with stress and danger. In a time where mental health professionals look for new and challenging identities, they have a tendency to abdicate from social psychiatric and public health activities in favour of more prestigious positions in brain research, genetics or advanced psychotherapy. A redefinition, reconceptualization and renaissance of social psychiatry seems timely and necessary, responding to the burden, advances and possibilities related to mental health we find today. It should proceed from the reductionism which often has characterized earlier psychosocial and social psychiatric approaches, utilize modern knowledge about neuroplasticity, psychoimmunology, neuropsychology and neurophilosophy, reflect the interaction between environment and structure, nature and nurture, and integrate different areas of knowledge in a holistic public mental health approach. Political decisions and societal solutions can be more or less in line with basic human preconditions. Consequences of failure to respect this already can be seen. A new awareness and responsibility-taking with regard to basic human ethological, physiological, psychological and existential conditions is needed and has to be concretized in innovative public mental health approaches.
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Authors: S E Jones, M W Schottstaedt, L A Duncan, R L Kirby, R H Good, R G Mennel, T K George, D A Snyder, D L Watkins, C A Denham, F A Hoyes, A S Rubin
Journal: Journal of Clinical Oncology (1996)

To determine the effects of sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) on the incidence, duration, and complications of myelosuppression after moderate-dose fluorouracil, doxorubicin, cyclophosphamide (FAC) adjuvant chemotherapy in patients with node-positive breast cancer.In this randomized, double-blind, placebo-controlled study, 142 women with stage II and III breast cancer were to receive four 21-day cycles of chemotherapy that consisted of fluorouracil 600 mg/ m2 intravenously (IV), doxorubicin 60 mg/m2 IV, and cyclophosphamide 750 mg/m2 IV on day 1, followed by placebo or GM-CSF 250 micrograms/m2/d daily subcutaneously (SC) on days 3 through 15. All patients received prophylactic ciprofloxacin by mouth when the absolute neutrophil count (ANC) was less than 1,000/microL.Eighty-six percent of GM-CSF patients (n = 62) and 96% of placebo patients (n = 69) completed four assessable cycles of treatment on study. Overall, the median duration of severe neutropenia (ANC < 500/microL) was 2.8 days with GM-CSF and 6.8 days with placebo (P < .001); the duration of ANC less than 1,000/microL was 6.0 versus 9.1 days, respectively (P < .001). Hospitalizations for febrile neutropenia were uncommon in either group: GM-CSF, six; placebo, eight. The only other difference in hematologic toxicity was grade 3/4 thrombocytopenia observed with greater frequency in GM-CSF patients than placebo patients in cycles 3 and 4. GM-CSF increased mean the FAC dose-intensity among patients who completed two or more cycles (P < .001). GM-CSF was generally well tolerated and associated with more injection-site reactions, but less mucositis than placebo. There were no deaths on study.GM-CSF significantly enhanced ANC recovery after FAC chemotherapy; it decreased the incidence and duration of associated neutropenia and moderately increased the dose-intensity of adjuvant chemotherapy. Whether these effects will ultimately translate into improved long-term outcome remains to be determined.